Catherine Arnaud

Catherine Arnaud

Auto-generated profile, based on publicly available information

Catherine Arnaud

Center for Epidemiology and Research in POPulation health (CERPOP), UMR1295, Toulouse University, Inserm, Toulouse, France; Clinical Epidemiology Unit, Toulouse University Hospital, Toulouse, France

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2022 in Developmental Medicine & Child Neurology
Verified
Journal Article
Open access
SMSarah McIntyre
Sarah McIntyre
SGShona Goldsmith
Shona Goldsmith
AWAnnabel Webb
Annabel Webb
VEVirginie Ehlinger
Virginie Ehlinger
SHSandra Julsen Hollung
Sandra Julsen Hollung
KHKate Himmelmann
Kate Himmelmann
Aim: To determine trends and current estimates in regional and global prevalence of cerebral palsy (CP).Method: A systematic analysis of data from participating CP registers/surveillance systems and population‐based prevalence studies (from birth year 1995) was performed. Quality and risk of bias were assessed for both data sources. Analyses were conducted for pre‐/perinatal, postnatal, neonatal, and overall CP. For each region, trends were statistically classified as increasing, decreasing, heterogeneous, or no change, and most recent prevalence estimates with 95% confidence intervals (CI) were calculated. Meta‐analyses were conducted to determine current birth prevalence estimates (from birth year 2010).Results: Forty‐one regions from 27 countries across five continents were represented. Pre‐/perinatal birth prevalence declined significantly across Europe and Australia (11 out of 14 regions), with no change in postneonatal CP. From the limited but increasing data available from regions in low‐ and middle‐income countries (LMICs), birth prevalence for pre‐/perinatal CP was as high as 3.4 per 1000 (95% CI 3.0–3.9) live births. Following meta‐analyses, birth prevalence for pre‐/perinatal CP in regions from high‐income countries (HICs) was 1.5 per 1000 (95% CI 1.4–1.6) live births, and 1.6 per 1000 (95% CI 1.5–1.7) live births when postneonatal CP was included.Interpretation: The birth prevalence estimate of CP in HICs declined to 1.6 per 1000 live births. Data available from LMICs indicated markedly higher birth prevalence.What this paper adds: • Birth prevalence of pre‐/perinatal cerebral palsy (CP) in high‐income countries (HICs) is decreasing.• Current overall CP birth prevalence for HICs is 1.6 per 1000 live births.• Trends in low‐ and middle‐income countries (LMICs) cannot currently be measured.• Current birth prevalence in LMICs is markedly higher than in HICs.• Active surveillance of CP helps to assess the impact of medical advancements and social/economic development.• Population‐based data on prevalence and trends of CP are critical to inform policy.

1 February 2011 in The Lancet Neurology
Verified
Journal Article
Closed access
FCFrançois Chollet
François Chollet
JTJean Tardy
Jean Tardy
JAJean-François Albucher
Jean-François Albucher
CTClaire Thalamas
Claire Thalamas
EBEmilie Berard
Emilie Berard
ILIsabelle Loubinoux
Isabelle Loubinoux

1 March 2008 in The Lancet
Verified
Journal Article
Closed access
BLBéatrice Larroque
Béatrice Larroque
PAPierre-Yves Ancel
Pierre-Yves Ancel
SMStéphane Marret
Stéphane Marret
LMLaetitia Marchand
Laetitia Marchand
MAMonique André
Monique André
MKMonique Kaminski
Monique Kaminski

1 March 2015 in JAMA Pediatrics
Verified
Journal Article
Open access
PDF file
PAPierre-Yves Ancel
Pierre-Yves Ancel
FGFrançois Goffinet
François Goffinet
PKPierre Kuhn
Pierre Kuhn
BLBruno Langer
Bruno Langer
JMJacqueline Matis
Jacqueline Matis
MKMonique Kaminski
Monique Kaminski
Previous cohort studies1-7 suggest that survival of infants born before 27 weeks’ gestation has improved during the past 2 decades. However, disability rates remain high at these gestational ages.8-10 Moreover, countries differ substantially in their organization of care, available resources, national laws, and cultural preferences regarding provision of proactive care. Therefore, to provide the best available information for parents and medical staff to use in making treatment decisions, mortality and morbidity must be monitored, and studies should be conducted in countries with different attitudes toward active care at early gestational ages.

16 August 2017 in BMJ
Verified
Journal Article
Open access
PDF file
VPVéronique Pierrat
Véronique Pierrat
LMLaetitia Marchand-Martin
Laetitia Marchand-Martin
CACatherine Arnaud
Catherine Arnaud
MKMonique Kaminski
Monique Kaminski
MRMatthieu Resche-Rigon
Matthieu Resche-Rigon
PAPierre-Yves Ancel
Pierre-Yves Ancel
Objectives To describe neurodevelopmental outcomes at 2 years corrected age for children born alive at 22-26, 27-31, and 32-34 weeks’ gestation in 2011, and to evaluate changes since 1997. Design Population based cohort studies, EPIPAGE and EPIPAGE-2. Setting France. Participants 5567 neonates born alive in 2011 at 22-34 completed weeks’ gestation, with 4199 survivors at 2 years corrected age included in follow-up. Comparison of outcomes reported for 3334 (1997) and 2418 (2011) neonates born alive in the nine regions participating in both studies. Main outcome measures Survival; cerebral palsy (2000 European consensus definition); scores below threshold on the neurodevelopmental Ages and Stages Questionnaire (ASQ; at least one of five domains below threshold) if completed between 22 and 26 months corrected age, in children without cerebral palsy, blindness, or deafness; and survival without severe or moderate neuromotor or sensory disabilities (cerebral palsy with Gross Motor Function Classification System levels 2-5, unilateral or bilateral blindness or deafness). Results are given as percentage of outcome measures with 95% confidence intervals. Results Among 5170 liveborn neonates with parental consent, survival at 2 years corrected age was 51.7% (95% confidence interval 48.6% to 54.7%) at 22-26 weeks’ gestation, 93.1% (92.1% to 94.0%) at 27-31 weeks’ gestation, and 98.6% (97.8% to 99.2%) at 32-34 weeks’ gestation. Only one infant born at 22-23 weeks survived. Data on cerebral palsy were available for 3599 infants (81.0% of the eligible population). The overall rate of cerebral palsy at 24-26, 27-31, and 32-34 weeks’ gestation was 6.9% (4.7% to 9.6%), 4.3% (3.5% to 5.2%), and 1.0% (0.5% to 1.9%), respectively. Responses to the ASQ were analysed for 2506 children (56.4% of the eligible population). The proportion of children with an ASQ result below threshold at 24-26, 27-31, and 32-34 weeks’ gestation were 50.2% (44.5% to 55.8%), 40.7% (38.3% to 43.2%), and 36.2% (32.4% to 40.1%), respectively. Survival without severe or moderate neuromotor or sensory disabilities among live births increased between 1997 and 2011, from 45.5% (39.2% to 51.8%) to 62.3% (57.1% to 67.5%) at 25-26 weeks’ gestation, but no change was observed at 22-24 weeks’ gestation. At 32-34 weeks’ gestation, there was a non-statistically significant increase in survival without severe or moderate neuromotor or sensory disabilities (P=0.61), but the proportion of survivors with cerebral palsy declined (P=0.01). Conclusions In this large cohort of preterm infants, rates of survival and survival without severe or moderate neuromotor or sensory disabilities have increased during the past two decades, but these children remain at high risk of developmental delay.

1 June 2007 in The Lancet
Verified
Journal Article
Closed access
HDHeather O Dickinson
Heather O Dickinson
KPKathryn N Parkinson
Kathryn N Parkinson
URUlrike Ravens-Sieberer
Ulrike Ravens-Sieberer
GSGiorgio Schirripa
Giorgio Schirripa
UTUte Thyen
Ute Thyen
ACAllan Colver
Allan Colver